Korea Research Institute of Bioscience and Biotechnology

Suk-Jin Yang

Young Il Yeom

Kyung Chan Park

Hyang-Sook Yoo

Tae Woo Kim

Dong Chul Lee

Yejin Jang

Jung Ju Lee

Jong Young Choi

In Young Park

Byung-Jung Choi

Zee-Yong Park

Hyun Ahm Shon

Yun Kyung Kang

Bo Hwa Sohn

The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.

Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer

The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status

Growing community of inventors

Daejeon, South Korea

Suk-Jin Yang